BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jenner AL, Aogo RA, Alfonso S, Crowe V, Deng X, Smith AP, Morel PA, Davis CL, Smith AM, Craig M. COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes. PLoS Pathog 2021;17:e1009753. [PMID: 34260666 DOI: 10.1371/journal.ppat.1009753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Farhang-sardroodi S, Ghaemi MS, Craig M, Ooi HK, Heffernan JM. . MBE 2022;19:5813-31. [DOI: 10.3934/mbe.2022272] [Reference Citation Analysis]
2 Zarnitsyna VI, Gianlupi JF, Hagar A, Sego TJ, Glazier JA. Advancing therapies for viral infections using mechanistic computational models of the dynamic interplay between the virus and host immune response. Curr Opin Virol 2021;50:103-9. [PMID: 34450519 DOI: 10.1016/j.coviro.2021.07.007] [Reference Citation Analysis]
3 Lasso G, Khan S, Allen SA, Mariano M, Florez C, Orner EP, Quiroz JA, Quevedo G, Massimi A, Hegde A, Wirchnianski AS, Bortz RH 3rd, Malonis RJ, Georgiev GI, Tong K, Herrera NG, Morano NC, Garforth SJ, Malaviya A, Khokhar A, Laudermilch E, Dieterle ME, Fels JM, Haslwanter D, Jangra RK, Barnhill J, Almo SC, Chandran K, Lai JR, Kelly L, Daily JP, Vergnolle O. Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes. PLoS Comput Biol 2022;18:e1009778. [PMID: 35041647 DOI: 10.1371/journal.pcbi.1009778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bai Y, Shen M, Zhang L. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment. Viruses 2022;14:763. [DOI: 10.3390/v14040763] [Reference Citation Analysis]
5 Ward B, Yombi JC, Balligand J, Cani PD, Collet J, de Greef J, Dewulf JP, Gatto L, Haufroid V, Jodogne S, Kabamba B, Pyr dit Ruys S, Vertommen D, Elens L, Belkhir L. HYGIEIA: HYpothesizing the Genesis of Infectious Diseases and Epidemics through an Integrated Systems Biology Approach. Viruses 2022;14:1373. [DOI: 10.3390/v14071373] [Reference Citation Analysis]
6 Vrachatis DA, Papathanasiou KA, Giotaki SG, Raisakis K, Kossyvakis C, Kaoukis A, Kolokathis F, Deftereos G, Iliodromitis KE, Avramides D, Bogossian H, Siasos G, Giannopoulos G, Reimers B, Lansky A, Tardif JC, Deftereos S. Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine. J Clin Med 2021;10:5128. [PMID: 34768648 DOI: 10.3390/jcm10215128] [Reference Citation Analysis]
7 Contreras C, Newby JM, Hillen T. Personalized Virus Load Curves for Acute Viral Infections. Viruses 2021;13:1815. [PMID: 34578396 DOI: 10.3390/v13091815] [Reference Citation Analysis]
8 Yin Y, Xi Y, Xu C, Sun Q. The Basic Reproduction Number and Delayed Action of T Cells for Patients Infected with SARS-CoV-2. Mathematics 2022;10:2017. [DOI: 10.3390/math10122017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 El Karkri J, Boudchich F, Volpert V, Aboulaich R. Stability Analysis of a Delayed Immune Response Model to Viral Infection. Differ Equ Dyn Syst. [DOI: 10.1007/s12591-022-00594-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Howell R, Clarke MA, Reuschl A, Chen T, Abbott-imboden S, Singer M, Lowe DM, Bennett CL, Chain B, Jolly C, Fisher J. Executable network of SARS-CoV-2-host interaction predicts drug combination treatments. npj Digit Med 2022;5. [DOI: 10.1038/s41746-022-00561-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang S, Hao M, Pan Z, Lei J, Zou X. Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients. PLoS Comput Biol 2021;17:e1009587. [PMID: 34818337 DOI: 10.1371/journal.pcbi.1009587] [Reference Citation Analysis]